allerg rhiniti develop drug product treatment guidanc industri us depart health human servic food drug administr center drug evalu research cder septemb 2018 clinicalmed allerg rhiniti develop drug product treatment guidanc industri addit copi avail offic commun divis drug inform center drug evalu research food drug administr 10001 new hampshir ave hillandal bldg 4th floor silver spring md 20993 0002 phone 8555433784 301 7963400 fax 3014316353 email druginfofdahhsgov httpswwwfdagovdrugsguidancecomplianceregulatoryinformationguidancesdefaulthtm us depart health human servic food drug administr center drug evalu research cder septemb 2018 clinicalmed tabl content introduct 1 ii backg round 2 iii overal consideratio ns adult program 2 number trial 2 b dose 3 c safeti monitor 3 corticosteroid specif issu 4 e issu specif topic product 4 iv overal consideratio ns pediatr progr 5 pediatr dose select 5 b safeti data 5 c corticosteroid specif issu 5 v protocol issu element 6 trial design 6 b inclu sion criteria 7 c exclus criteria 7 blind 8 e formul dosag regimen 9 f evalu 9 1 assess patient complianc 9 2 assess rescu medic use 9 3 rate system 9 4 record score 10 5 advers event record 10 vi data analysi issu 10 symptom score 10 b onset action 11 vii fix dose combinati product 12 contain nonbind recommend 1 allerg rhiniti develop drug product treatment guidanc industry1 guidanc repres current think food drug administr fda agenc topic establish right person bind fda public use altern approach satisfi requir applic statut regul discuss altern approach contact fda offic respons gui danc list titl page introduct purpos guidanc assist sponsor develop drug product treatment allerg rhiniti children adult 2 guidanc address issu trial design effect safeti new product develop treatment season allerg rhiniti sar perenni allerg rhiniti par recommend guidanc base assess import issu rais revi ew adult pediatr allerg rhiniti clinic trial agenc current understand mechan two relat disord sar par pathophysiolog sar par similar term chemic mediat produc endorgan manifest differ two entiti primarili base caus durat diseas trial design issu pertain sar par trial also similar thu two categori treat collectivel guidanc allerg rhiniti differ recommend design sar par trial indic sponsor encourag discuss detail trial design specif issu relat individu product divis revi w staff conduct clinic trial guidanc contain discuss gener issu statist analysi clinic trial design topic address ich guidanc industri e9 statist principl clinic trial e10 choic control group relat issu clinic 1 guidanc prepar divis pulmonari allergi rheumatolog product center drug evalu research food drug administr 2 purpos guidanc term drug product inclus small larg molecul activ moieti moieti formul along deliveri devic applic contain nonbind recommend 2 trial respect 3 well draft ich guidanc industri e9r1 statist principl clinic trial addendum estimand sensit analysi clinic tri als4 gener fda guidanc document establish legal enforc respons instead guidanc describ agenc current think topic view recommend unless specif regulatori statutori r equir cite use word agenc guidanc mean someth suggest recommend requir ii background inform pathophysiolog treatment allerg rhiniti subtyp sar par grown markedli past decad patient allerg rhiniti may nasal non nasal symptom main nasal symptom allerg rhiniti nasal itch ie nasal pruritu sneez rhinorrhea nasal congest nasal pruritu sneez induc sensori nerv stimul wherea congest result vasodil result engorg cavern sinusoid rhinorrhea induc increas vascular permeabl well direct glandular secret import non nasal symptom commonli associ allerg rhiniti includ eye itch tear eye red itch ear andor palat grow number chemic mediat believ contribut allerg rhiniti desp ite differ caus tempor pattern diseas group chemic mediat appear regul respons sar par reason distinct sar par term clinic trial design made ly clinic relev area iii overal consideratio ns adult program number trial approv new molecular entiti adult agenc recommend least two adequ well control phase 3 clinic trial support either sar par indic altern sponsor submit one sar one par trial support indic adequ well control phase 3 trial demonstr safeti effect drug indicat ion drug approv one two relat indic singl trial may support approv indic exampl singl par trial may support approv par indic drug alreadi approv sar 3 updat guidanc period recent version guidanc check fda guidanc web page httpswwwfdagovregulatoryinformationguidancesdefaulthtm 4 final guidanc repres fda current think topic recent version guidanc check fda guidanc web page httpswwwfdagovregulatoryinformationguidancesdefaulthtm contain nonbind recommend 3 b dose dose respons relationship n investig product evalu trial dedic dose rang trial goal dose explor identifi optim dose dose frequenc balanc benefit risk ideal dose explor conduct real world set exposur model park inhal chamber trial may predict real world clinic respons likewis dose select base clinic meaning endpoint pharmacodynam pd marker may predict c safeti monitor clinic efficaci trial must also address safeti concern monitor advers event perform routin laboratori test ie blood chem istri liver function test complet blood count differenti urinalys electrocardiogram appropri 21 cfr 31223a6 sar par phase 3 trial routin laboratori test recommend trial patient least initi screen last visit product system bioavail agenc recommend safeti program includ thorough cardiac safeti evalu gener risk clinic signific qt prolong would render ri kbenefit unfavor allerg rhiniti product intend symptomat benefit clinic electrocardiograph evalu perform earli clinic develop clinic trial assess potenti product delay cardiac repolar describ detail ich guidanc ndustri e14 clinic evalu qtqtc interv prolong proarrhythm potenti non antiarrhythm drug sponsor encourag contact review divis regard appropr iat cardiac safeti monitor respect develop program class product sponsor may wish provid assess degre sedat compar placebo safeti databas adequ assess sedatio n primarili base individu patient advers event report sedat andor drowsi similar terminolog defin sponsor advers event dictionari need addit evalu drive simul trial depend characterist intend use individu product long term safeti data includ least 300 patient evalu 6 month 100 patient evalu 1 year overal patient databas includ least 1 500 patient recommend suffici number patient receiv highest dose propos market see ich guidanc industri e1a extent popul exposur assess clinic safeti drug intend long term treatment non lifethreaten condit measur efficaci endpoint recommend long term safeti trial secondari assess contain nonbind recommend 4 corticosteroid specif issu import safeti issu intranas corticosteroid ordinarili addr ssed adult clinic program includ assess adren function use either 24 hour urinari free cortisol level 24 hour plasma cortisol area curv level measur pretreat least 6 week treatment inv stigat product placebo activ control recommend trial evalu possibl cataract format long term trial slit lamp examin pre post treatment evalu glaucoma long term trial use ntraocular pressur monitor pre post treatment e issu specif topic product given risk local toxic safeti monitor includ baselin serial nasal examin p respecifi grade criteria assess presenc nasal irrit eg mucos edema erythema epistaxi ulcer septal perfor use document chang cours treatment period whole product includ dedic deliveri system consid drug devic combin product defin 21 cfr 32e chang formul excipi formul flow path within devic devic compon eg dimens materi construct coat alter deliveri characterist affect clinic perform user interfac product therefor recommend key trial develop program includ dose rang trial confirmatori efficaci safeti trial conduct tobemarket product furthermor data provid perform reliabl new deliveri system period intend use vitro clinic bridg data may need support chang formul deliveri system depend natur extent chang alter product may view new product necessit separ develop program efficaci safeti trial recommend sponsor discuss plan chang topic product review divis bridg studi nasal product local action particularli product suspens state substanti undertak principl may appli bridg program outlin n draft guidanc ndustri bioavail bioequival studi nasal aerosol nasal spray local action 5 5 final guidanc repres fda current think topic recent version guidanc check fda guidanc web page httpswwwfdagovregulatoryin formationguidancesdefaulthtm contain nonbind recommend 5 iv overal consideratio ns pediatr progr pediatr age rang propos product particularli young patient justifi sponsor base preval diseas need treatment age group product indic treatment sar gener evalu children age 2 year product indic treatment par evalu children age 6 month opic product appropri deliveri system propos age rang addit consider sponsor encourag discuss specif pediatr program divis case bycas basi begin discuss pediatr formul clinic develop plan earli feasibl sponsor requir submit pediatr studi plan und r pediatr research equiti act later 60 day end ofphas 2 meet recommend sponsor refer pediatr research equiti act amend food drug administr safeti innov act 6 pediatr dose select product alreadi approv andor adequ studi adult yet studi children appropri pediatr dose determin addit adequ short long term safeti inform propos pediatr age group provid oral formul reason pharmacokinet pk pd link efficaci establish pk data children use determin compar exposur adult patient therefor appropri pediatr do e intranas formul efficaci trial pediatr patient recommend plasma drug level consist detect reliabl measur local bioavail topic efficaci b safeti data typic 3 month addit specif pediatr safeti data intranas product 1 month addit specif pediatr safeti data oral product recommend suggest se data collect control trial howev durat number pediatr patient expos investig product safeti monitor determin individu basi product base anticip side effect pediatr pk data safeti concern c corticosteroid specif issu intranas corticosteroid recommend 6 week hypothalam pituitari adren hpa axi trial placebo activ control trial intend evalu influenc 6 see section 505be feder food drug cosmet act amend section 506 food drug administr safeti innov act draft guidanc industri pediatr studi plan cont nt process submit initi pediatr studi plan amend initi pediatr studi plan final guidanc repres fda current think topic recent version guidanc check fda guidanc web page httpswwwfdagovregulatoryinformationguidancesdefaulthtm contain nonbind recommend 6 product hpa axi limit hpa axi suppress alon ethic concern use oral prednison activ control adren respons trial children altern approach may appropri approach includ use approv intranas cortic osteroid suffici caus hpa axi effect base inform indic intranas corticosteroid potenti decreas growth veloc children growth trial recommend prepubert children trial conduct postapprov may use sponsor includ knemometri trial new drug applic provid pd growth data consider initi review recommend regard design conduct growth tri al outlin guidanc ndustri oral inhal intranas corticosteroid evalu effect growth children sponsor encourag discuss detail pediatr growth trial design review divis v protocol issu element trial design follow gener recommend trial design phase 3 allerg rhiniti sar par trial doubl blind placebo control parallel group trial recommend prefer placebo run period placebo run period use assess minimum level complianc symptom sever doubl blind treatment period suggest durat doubl blind treatment period least 2 week sar trial 4 week par trial sar trial agenc recommend protocol includ plan measur pollen count differ trial center final report document exposur patient relev allergen trial period may also help collect data number raini day trial extent patient exposur outdoor air sar trial encourag random patient within center doubl blind portion short time period gener reduc variabl allergen exposur time period random shortest period feasibl given size trial variabl weather mani patient par may concomit sar therefor help par efficaci trial conduct time relev season allergen less abund therefor less like influenc trial result contain nonbind recommend 7 b inclus criteria follow gener recommend inclus criteria phase 3 allerg rhiniti trial sar trial older children adolesc adult recommend patient histori sar minimum 2 year trial entri agenc recommend document sensit posit skin test prick intraderm method adequ valid vitro test specif immunoglobulin e ige eg radioallergosorb test rast paper radioimmunosorb test prist relev season allergen geograph area trial within 12 month enrol gener posit skin test defin wheal greater equal 3 millimet mm larger diluent control eryth ema prick test greater equal 7 mm larger diluent control erythema intraderm test posit vitro test determin standard individu refer laboratori posit skin test vitro test specif ige correl allergi histori result accept meet inclus criteria par trial allergi perenni allergen eg dust mite cockroach cat dog mold demonstr trial pa tient prick intraderm skin test use criteria posit adequ valid vitro test specif ige eg rast prist suggest test perform 12 month enrol pat ient relev allergi histori test allergen agenc recommend patient start immunotherapi chang dose approxim 1 month preced enrol trial ideal p atient maintain sa dose throughout trial patient experienc symptom meet exceed appropri minimum level time trial enrol ensur assess sever symptom primari endpoint requir least moder sever major individu symptom defin trial symptom score scale c exclus criteria follow gener recommend ation exclus criteria phase 3 allerg rhiniti trial asthma except mild intermitt asthma 7 lessen confound asthma medic may modifi allerg rhiniti 7 see nation heart lung blood institut nation asthma educ prevent pro gram expert panel report 3 guidelin diagnosi manag asthma http wwwnhlbinihgovhealth proguidelinescurrentasthma guidelinesindexhtm contain nonbind recommend 8 chronic intermitt use inhal oral intramuscular intraven andor potent topic corticosteroid use leukotrien modifi use long act antihistamin prohibit medic inadequ washout period certain drug class follow washout period gener suffici intranas system corticosteroid 1 mon th leukotrien modifi 1 month intranas cromolyn 2 week intranas system decongest 3 day cetirizin fexofenadin loratadin desloratadin hydroxyzin 5 10 day intranas antihistamin 3 day system antihistamin 3 day document evid acut signific chronic sinus determin individu investig chronic use concomit medic eg tricycl antidepress would affect assess effect inv tigat product histori hypersensit product excipi presenc rhiniti secondari caus presenc ocular herp simplex cataract intranas corticosteroid trial histori glaucoma intr anas corticosteroid anticholinerg trial plan travel outsid trial area substanti portion trial period blind allerg rhiniti trial base subject endpoint blind critic consider process ensur blind investig product describ protocol doubl blind possibl rational provid along discuss mean reduc elimin bia topic n asal formul descript differ appear activ placebo treatment protocol eg differ devic odor characterist formul help determin adequaci trial blind contain nonbind recommend 9 e formul dosag regimen sponsor encourag provid inform protocol specif formul use market product placebo along descript dose regimen recommend dose rang confirmatori trial use bemarket product sponsor address safeti effect studi formul bridg bemarket formul bridg one formul anoth propos inform formul composit trial lot includ final report respect product f evalu follow gener recommend trial assess phase 3 allerg rhiniti trial 1 assess patient complianc protocol final report provid inform complianc investig product use determin document throughout trial noncompli dealt 2 assess rescu medic use rescu medic allow trial protocol document rescu medic use analyz differ treatment group recommend inclus section clinic tr ial report present rescu medic use differ treatment group 3 rate system prefer measur efficaci allerg rhiniti trial patient self rate instantan reflect total nasal symptom score summ score gener includ follow four nasal symptom rhinorrhea nasal congest nasal itch sneez rate 0 3 scale sever addit delet symptom total score appropri base mech anism action chang discuss review divis patient rate score prefer primari measur effect common allerg rhiniti rate system use clinic trial follow 0 3 scale 0 absent symptom signsymptom evid 1 mild symptom signsymptom present minim awar easili toler 2 moder symptom definit awar signsymptom bothersom toler contain nonbind recommend 10 3 sever symptom si gnsymptom hard toler caus interfer activ daili live andor sleep regardless score system chosen detail descript symptom rate scale provid patient includ inst ruction proper complet symptom diari definit differ categori scale 8 4 record score agenc recommend patient instruct record symptom score diari least often daili ose interv collect reflect symptom score ie evalu symptom sever predefin time period 12 hour instantan symptom score ie evalu symptom sever immedi next dose recommend reflect symptom score assess overal degre effect prespecifi time interv wherea instantan score assess effect end ofdos interv use assess onset action 5 advers event record recommend advers event record daili patient diari record addit elicit trial staff clinic visit vi data analysi issu symptom core symptom score collect baselin daili cours trial collect baselin symptom score sever day immedi preced patient random permit evalu baselin compar variou treatment arm well determin treatment effect time appropri primari efficaci endpoint chang baselin reflect total nasal symptom score tnss averag entir doubl blind treatment period 2 week sar 4 week par depend drug class evalu tnss defin total score compos least three follow four nasal symptom rhinorrhea nasal congest nasal itch sneez inclus nasal congest tnss may appropria te intranas corticosteroid decongest may appropri antihistamin anticholinerg cromolyn like agent appropri key secondari endpoint chang baselin instantan tnss across doubl blind treatment period assess appropri dose interv 8 see guidanc industri patient report outcom measur use medic product develop support label claim contain nonbind recommend 11 develop program demonstr signific differ product placebo end dose interv averag across doubl blind treatment p eriod design allerg rhiniti protocol sponsor encourag numer defin clinic meaning chang primari efficaci endpoint provid rational select statist section protocol includ power calcul use valu nd shoul prospect discuss miss data handl analysi plan particular protocol defin primari estimand ie primari measur treatment effect estim ate clinic trial justifi estimand estim minim plausibl assumpt furthermor recommend continu collect efficaci safeti data treatment discontinu rescu medic use faci litat evalu treatment polici estimand addit evalu effect product entir doubl blind period addit data present help evalu effect includ present morn ing even symptom score separ reflect instantan symptom assess present efficaci data first day trial separ reflect instantan symptom assess data present also separ morn even score allow assess onset action present efficaci data week individu reflect instantan symptom assess allow determ inat onset action durabl respons cours clinic trial present efficaci data individu compon symptom score compris total symptom complex patient rate physician rate measur includ secondari efficaci endpoint exampl assess ocular symptom associ allerg rhiniti may applic certain product patient rate reflect instantan total ocular symptom score similar symptom score system use nasal symptom use support inclus relev inform label inform diseas specif qualiti oflif measur also consid inclus label anti cipat r eplic data least two trial support inclus measur label b onset action definit onset action allerg rhiniti product point patient might reason expect see meaning decreas allerg rhiniti symptom purpos allerg rhiniti first time point initi treatment product demonstr greater chang baselin n primari efficaci endpoint compar contain nonbind recommend 12 placebo treatment prove durabl point end propos dose interv onset action inform may includ label least two trial recommend support particular onset action claim use assess onset action develop regardless propos claim two trial ident design evalu sar par onset action larg pd issu number differ trial design use follow three type use 1 standard phase 3 allerg rhiniti efficaci trial symptom score data collect frequent first day 2 singl dose parallel group placebo control trial patient park set patient expos relev outdoor season allergen follow dose nasal symptom evalu hourli basi 3 inhal chamber trial also known environment exposur unit eeu previous asymptomat patient expos relev allergen gener season allergen ragwe control indoor set follow dose nasal symptom evalu hourli basi onset ction data come three design howev eeu andor park trial use support onset action claim shorter onset action seen phase 3 trial agenc recommend result replic co nsider independ inform due shorter durat trial restrict set manner conduct case inform onset action deriv phase 3 trial use support appr oval also includ propos packag insert along data park chamber trial reflect real world set treatment trial vii fix dose combin product addit gener principl outlin 21 cfr 30050 regard develop fix dose combin product consider allerg rhiniti combin product includ follow contribut monotherapi compon support replic appropriatel design conduct trial combin product compar compon treatment differ compon combin product clinic meaning statist signific efficaci safet dose dose regimen individu compon establish ie monotherapi compon test effect dose dose regimen contain nonbind recommend 13 local act topic product pharmaceut differ combin product nd compon may obscur comparison combin product compon use clinic trial result commerci avail compar may appropri purpos factori compari ponsor like need develop monotherapi compar product specif purpos combin product develop program patient alreadi fail one compon combin product exclud unless scientif justif except given complex develop program fix dose local act combin product sponsor encourag discuss detail monotherapi compon trial design view divis earli develop program